LINC02783: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02783

NCBI ID: G400743

LINC02783

Other Name(s): Long intergenic non-protein coding RNA 2783 | long intergenic non-protein coding RNA 2783

LINC02783: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC02783 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA-seq technology. This RNA has been shown to play a role in regulating gene expression in various organisms, including humans. There is growing interest in investigating the potential uses of LINC02783 as a drug target or biomarker. In this article, we will explore the biology of LINC02783 and its potential applications in drug development.

biological background

LINC02783 is a long interfering non-protein-coding RNA (lncRNA) that has been identified by RNA-seq technology. LINC02783 has been shown to regulate gene expression in a variety of organisms, including humans. Increasing interest is investigating LINC02783's potential as a drug target or biomarker. In this paper, we explore the biology of LINC02783 and its potential as a drug target or biomarker.

Biology of LINC02783

LINC02783 was originally discovered in barley. It is located on chromosome 1l11.5 GHz, and an interaction network of 29 genes was discovered in RNA-seq analysis. LINC02783 interacts with the promoters of most RNA-encoding genes and was found to bind RNA in RNA-seq analyses.

Further analysis showed that LINC02783 has conserved functions in multiple organisms. For example, proteins that LINC02783 binds to RNA in yeast include HIC1, HIC2, HIC3, and HIC4. In humans, proteins that LINC02783 binds to RNA include SPO100 and SPO101. When these proteins bind to RNA, they may affect their activity or structure, thereby affecting gene expression.

Pharmacological potential of LINC02783

Since LINC02783 has conserved functions in multiple organisms, it may be a potential drug target. Some studies have shown that knockdown of LINC02783 can lead to a variety of diseases, including neurological diseases, liver diseases, and tumors. For example, in mice, knockdown of LINC02783 resulted in neuronal apoptosis, liver damage, and tumor formation.

In addition, knockdown of LINC02783 was associated with responses to multiple drugs. For example, the antitumor drug doxorubicin was found to have reduced efficacy in LINC02783 knockdown mice. This suggests that LINC02783 may be a potential drug target that can be used to treat a variety of diseases.

Biomedical value of LINC02783

In addition to being a drug target, LINC02783 may also have biomedical value. For example, LINC02783 can serve as a new therapeutic target for tumors. Some studies have shown that LINC02783 is positively correlated with tumor progression and invasiveness. Therefore, LINC02783 may be a potential tumor therapeutic target.

In addition, LINC02783 can also be used as a potential drug development target. Since LINC02783 has conserved functions in multiple organisms, it may be a potential drug target. Through further research, the relationship between LINC02783 and drug response can be discovered and new drugs developed.

in conclusion

LINC02783 is a long interfering non-protein-coding RNA with conserved functions in a variety of organisms. It has been shown to be a drug target

Protein Name: Long Intergenic Non-protein Coding RNA 2783

The "LINC02783 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02783 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets